A phase I study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.

Trial Profile

A phase I study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2013

At a glance

  • Drugs Sirolimus (Primary) ; Bevacizumab
  • Indications Liver cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top